| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dinaciclib | CTRPv2 | pan-cancer | AAC | -0.074 | 0.2 |
| mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.2 | 0.2 |
| mRNA | valdecoxib | CTRPv2 | pan-cancer | AAC | 0.053 | 0.2 |
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | 0.059 | 0.2 |
| mRNA | bafilomycin A1 | CTRPv2 | pan-cancer | AAC | -0.22 | 0.2 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.056 | 0.2 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | 0.046 | 0.2 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.067 | 0.2 |
| mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | 0.083 | 0.2 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.043 | 0.2 |